David R. Bauer
Lawyers
Filters
Editas Medicine $125 million follow-on offering
The stock is listed on the Nasdaq Global Select Market
Akoya Biosciences $50 million follow-on offering
The stock is listed on Nasdaq
Ionis Pharmaceuticals $575 million convertible senior notes offering
The 1.75% convertible senior notes are due 2028
Oculis Holding $40.25 million debut equity offering
The shares are listed on the Nasdaq Global Market
TScan Therapeutics $140.6 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Emergent BioSolutions $150 million at-the-market offering
The shares are listed on the NYSE
Forbion European Acquisition combination with enGene
We are advising Forbion European Acquisition on its de-SPAC transaction
Bloom Energy $632.5 million green convertible notes and capped call transactions
The 3% green convertible senior notes are due 2028
Schlumberger $1 billion senior notes offering
The investment-grade notes are due 2028 and 2033
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction